<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732339</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH-2018-038</org_study_id>
    <nct_id>NCT03732339</nct_id>
  </id_info>
  <brief_title>CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial</brief_title>
  <acronym>CTCNeoBC</acronym>
  <official_title>Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemotherapy Among Locally Advanced Breast Cancer Patients: a Single-center, Prospective, Exploratory Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Viroad Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE
      approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in
      neoadjuvant chemotherapy among locally advanced breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">March 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predictive value of CTC in ypT0 ypN0</measure>
    <time_frame>Change from pre-chemotherapy to 22-28(±7) days after first dose of neoadjuvant chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Predictive value of CTC in ypT0, ypT0/is ypN0, near pCR</measure>
    <time_frame>before and 22-28(±7) days after first dose of neoadjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypersensitivity</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Number of participants with hypersensitivity as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection rate of GILUPI CellCollector®</measure>
    <time_frame>before and 22-28(±7) days after first dose of neoadjuvant chemotherapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Locally Advanced Breast Cancer</condition>
  <condition>Circulating Tumor Cell</condition>
  <arm_group>
    <arm_group_label>GILUPI CellCollector®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GILUPI CellCollector®</intervention_name>
    <description>Use of GILUPI CellCollector® to detect CTC</description>
    <arm_group_label>GILUPI CellCollector®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically confirmed primary invasive breast adenocarcinoma,
             anatomic stage T2-4N0-3M0 or T1N1-3M0 before neoadjuvant chemotherapy

          -  ECOG 0-1

          -  Adequate organ function

          -  Consent to undergo CTC analysis in vivo

        Exclusion Criteria:

          -  Pregnant or breastfeeding patients

          -  Metastatic or recurrent patients

          -  Uncontrollable infection
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinsong Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>February 1, 2020</last_update_submitted>
  <last_update_submitted_qc>February 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

